S1RA HCl is primarily investigated for its potential in treating neuropathic pain due to its action as a selective sigma-1 receptor antagonist. By blocking sigma-1 receptors in the central nervous system, it modulates pain signaling pathways, particularly those involved in chronic and nerve-related pain conditions. This makes it a promising candidate for conditions such as diabetic neuropathy, chemotherapy-induced neuropathy, and other central sensitization pain states where conventional analgesics provide limited relief. Preclinical studies have shown that S1RA HCl can enhance the efficacy of opioids and reduce the development of tolerance, suggesting possible use in combination therapies for improved pain management with lower opioid doses. It does not act on opioid receptors, minimizing the risk of respiratory depression or addiction typically associated with opioid drugs. Research is ongoing to evaluate its safety and effectiveness in clinical settings.